USFDA to re-audit Dr Reddy’s 3 plants


US Food and Drug Administration (USFDA) will re-audit three manufacturing facilities of Dr Reddy’s Laboratories in the current quarter.

The USFDA had issued a warning letter to the drug major on November 5, 2015 on three of its plants at Srikakulam, Miryalaguda and Duvvada after finding several violations with regard to current good manufacturing practices (CGMP)